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ABSTRACT  
 
Rationale 
Despite several large clinical trials assessing blood pressure lowering in acute stroke, 
equipoise remains, particularly for ischaemic stroke. The ‘Blood pressure in Acute 
Stroke Collaboration’ (BASC) commenced in the mid 1990s focusing on systematic 
reviews and meta-analysis of blood pressure lowering in acute stroke. From the start, 
BASC planned to assess safety and efficacy of blood pressure lowering in acute stroke 
using individual patient data. 
 
Aims 
To determine the optimal management of blood pressure in patients with acute 
stroke, encompassing both intracerebral haemorrhage and ischaemic stroke. 
Secondary aims are to assess which clinical and therapeutic factors may alter the 
optimal management of high blood pressure in patients with acute stroke and to 
assess the effect of vasoactive treatments on haemodynamic variables. 
 
Methods and design 
Individual patient data from randomised controlled trials of blood pressure 
management in participants with ischaemic stroke and/or intracerebral haemorrhage 
enrolled during the ultra-acute (pre-hospital), hyper-acute (<6 hours), acute (<48 
hours) and sub-acute (<168 hours) phases of stroke. 
 
Study outcomes 
The primary effect variable will be functional outcome defined by the ordinal 
distribution of the modified Rankin Scale; analyses will also be carried out in 
prespecified subgroups to assess the modifying effects of stroke-related and pre-
stroke patient characteristics. Key secondary variables will include clinical, 
haemodynamic and neuroradiological variables; safety variables will comprise death 
and serious adverse events. 
 
Discussion 
Study questions will be addressed in stages, according to the protocol, before 
integrating these into a final overreaching analysis. We invite eligible trials to join the 
collaboration. 
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INTRODUCTION AND RATIONALE 
 
High blood pressure is common in both acute ischaemic stroke and primary 
intracerebral haemorrhage, and is associated independently with poor short- and 
long-term outcome (1, 2). There is general agreement on intensive lowering of 
elevated blood pressure in intracerebral haemorrhage, as reflected in international 
guidelines based on the results of the INTERACT-2 trial (3-5); following publication of 
the neutral results of the ATACH-2 trial(6), guidelines have been further updated. 
Despite results of large clinical trials (7-9), equipoise remains regarding the question 
of whether to treat or not to treat blood pressure in patients with ischaemic stroke. 
Systematic reviews of trials of blood pressure management have been performed 
using published summary data and these suggest that lowering blood pressure in the 
first few hours after ischaemic stroke might be most effective (10). However, such 
meta-analyses neither allow effects to be assessed easily in subgroups nor multiple 
variable analyses. In contrast, meta-analyses using individual patient data facilitate 
these and are considered to be the gold-standard (11). Additional questions also need 
addressing, including the management of blood pressure before, during and after 
reperfusion therapies such as intravenous thrombolysis and mechanical 
thrombectomy. 
 
We detail the protocol by which the Blood Pressure in Acute Stroke Collaboration 
(BASC), an international collaborative individual patient data pooling project, will 
examine the results of randomised controlled trials with the intention of helping define 
the optimal management of blood pressure in acute stroke. 
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AIMS AND METHODS 
 
The Blood Pressure in Acute Stroke Collaboration (BASC) 
The BASC project commenced in the mid-1990s. Early work focused on developing 
systematic reviews and meta-analyses based on summary (group) data and these 
were published in the Cochrane Database of Systematic Reviews. The first review 
(2001) identified randomised controlled trials specifically aiming to alter blood 
pressure (BASC-1) and was followed by a wider review that included all trials 
involving a vasoactive drug, whether or not this was given to alter blood pressure 
(BASC-2). At this stage, there were insufficient data to lead to definitive conclusions 
on the management of blood pressure in acute stroke. These reviews have been 
updated periodically (10, 12). 
 
It was always intended that a third phase (BASC-3) would be based on individual 
patient data (IPD), and data were shared with the collaboration through to 2003. 
Since then, several larger clinical trials have been published and a detailed update is 
now warranted. The collaborative group consists of leading international investigators 
of individual clinical trials. 
 
The results will be published under the banner of BASC Collaborators, where allowed 
by journals. Collaborators will be listed in the appendix by trial. The papers will be 
written by a Publication Committee and then distributed to all Collaborators for 
comment, interpretation, changes and additions. Shared data will not be used for any 
purpose other than in collaborator-approved BASC analyses. 
 
Objectives 
The overall objective of BASC is to determine the optimal management of blood 
pressure in patients with acute stroke. Specific objectives are: 
1. To determine the optimal management of high blood pressure in patients with 
acute intracerebral haemorrhage. 
2. To determine the optimal management of high blood pressure in patients with 
acute ischaemic stroke. 
3. To assess which factors may alter the optimal management of high blood pressure 
in patients with acute stroke. 
4. To assess effects of different strategies (target blood pressure, intervention 
classes), and continuing versus stopping pre-stroke antihypertensive therapy. 
5. To assess the effect of vasoactive treatment on haemodynamic measures. 
6. To assess the effect of vasoactive treatment on neuroimaging outcomes. 
7. To increase understanding of the hypertensive response in acute stroke. 
 
Eligible Studies 
Randomised controlled trials of blood pressure management in acute stroke will be 
included involving participants with ischaemic stroke and/or intracerebral 
haemorrhage, and covering the ultra-acute (pre-hospital), hyper-acute (<6 hours), 
acute (<48 hours) and sub-acute (<168 hours) phases of stroke. Trials will be sought 
using electronic searches (Cochrane Library, EMBASE, PubMed and Web of Science) 
and in the reference lists of published systematic reviews and ad hoc reviews. Studies 
that have provisional investigator agreement for inclusion in BASC-3 are listed in the 
supplemental table. 
 
Data sharing 
Collaborators will be sharing data with the BASC Collaboration. Sharing will involve a 
formal contract between BASC and the sharing organisation to ensure transparency, 
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and predefined and appropriate use of data according to this BASC protocol. Data will 
be shared electronically, and stored on password-protected, encrypted hard disks in a 
locked room, with daily backup facilitating disaster recovery. 
 
Baseline variables 
Clinical data will include: 
 Demographic: Age, sex, country of recruitment, pre-morbid mRS 
 Medical history: Vascular risk factors 
 Haemodynamic parameters: systolic/diastolic blood pressure, heart rate, measures 
of variability 
 Stroke: type (ischaemic stroke, intracerebral haemorrhage, stroke mimics), 
severity (stroke scale), syndrome, level of consciousness (Glasgow Coma Scale) 
 Blood pressure treatment: time from onset to randomisation (as a surrogate for 
time to treatment), strategy (target blood pressure, intervention class), route of 
administration 
 
Imaging data will be collected from trials where this is available to assess acute stroke 
lesion characteristics: 
 Ischaemic stroke: infarct visibility, severity of attenuation change, extent, location, 
mass effect, intravascular thrombus, haemorrhagic transformation 
 Intracerebral haemorrhage: location, size, presence of intraventricular or 
subarachnoid blood 
 Both: pre-existing changes - brain atrophy, white matter lesions, prior stroke 
lesions 
 
 
STUDY OUTCOMES 
 
Primary outcome 
The primary effect variable will be functional outcome defined by the ordered 
distribution of the modified Rankin Scale (mRS) at the end of trial follow-up (3 or 6 
months). In the case of missing data, the last recorded score will be carried forward. 
Analyses will be carried out in the entire study population and then in prespecified 
subgroups, as identified in Table 1. Patients without available data, and where the 
above procedure for missing data cannot be applied, will be excluded from analyses. 
However, sensitivity analyses will use complete data based on multiple imputation 
where end-of-trial mRS is missing. 
 
Secondary outcomes 
The effect of blood pressure lowering treatment on secondary outcome variables will 
also be studied: 
 
Clinical parameters 
 Death or dependency at the end of follow-up (mRS 3-6) 
 Death or neurological deterioration (increase in NIHSS by >=4 points, or decrease 
in Glasgow Coma Scale by >=2 points (13)) at end of treatment 
 Death at end of treatment 
 Vascular death at end of follow-up (as defined by each individual trial) 
 Recurrent stroke (as defined by each individual trial) 
 Symptomatic hypotension (as defined by each individual trial) 
 Symptomatic hypertension (as defined by each individual trial) 
 
Haemodynamic measures 
 Systolic blood pressure (SBP) 
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 Diastolic blood pressure (DBP) 
 Mean arterial pressure (MAP) 
 Pulse pressure (PP = SBP-DBP) 
 Systolic blood pressure variability (SBPV = standard deviation for SBP) 
 Systolic blood pressure variability index (SBPVI = SBPV/SBP) 
 Heart rate (HR) 
 Heart rate variability (HRV = standard deviation for HR) 
 Heart rate variability index (HRVI = HRV/HR) 
 Rate pressure product (RPP = SBP x HR) 
 
Safety outcomes 
 Serious adverse events 
o Deep vein thrombosis or pulmonary embolism  
o Headache  
o Myocardial infarction 
o Pneumonia  
o Renal events 
 
Radiological outcomes during or at end of treatment 
 Acute changes, IS: Infarct volume, mass effect, hyperdense artery 
 Acute changes, ICH: Haematoma volume, perihaematoma oedema, mid-line shift, 
spot sign (if angiography) 
 General: Atrophy score, previous stroke lesions, white matter hyperintensity 
 
Proposed stages of BASC-3  
The analyses will be carried out in consecutive stages addressing specific study 
questions, before integrating these into a final overarching analysis. Individual 
statistical analysis plans for each stage will be finalised and published before data 
analysis. Trials for inclusion are listed in the Supplemental Table. 
1. Nitric oxide donors in acute stroke. To assess safety and efficacy of nitric oxide 
donors in acute stroke. This work has been published (14) and will be updated 
once ongoing trials (15) have reported. 
2. Continuation versus stopping pre-stroke antihypertensive therapy. To assess 
safety and efficacy of continuation versus stopping pre-stroke antihypertensive 
therapy in acute stroke. This work has been published (16). 
3. Primary intracerebral haemorrhage. To assess safety and efficacy of blood pressure 
lowering in patients with primary intracerebral haemorrhage. The analyses will 
include data from trials focussing on ICH alone, and ICH patients in trials studying 
a mixed population of stroke. 
4. Acute ischaemic stroke patients receiving thrombolysis. To assess safety and 
efficacy of blood pressure lowering in patients who receive thrombolysis. The 
analyses will include patient data from trials where thrombolysis was administered 
before blood pressure lowering, where thrombolysis was administered in parallel 
with blood pressure lowering, and where thrombolysis was administered after 
blood pressure lowering. 
5. Ischaemic stroke. To assess safety and efficacy of blood pressure lowering in 
patients with ischaemic stroke. The analyses will include data from trials focussing 
on ischaemic stroke alone, and ischaemic stroke patients in trials studying a mixed 
population of stroke. 
6. All stroke. To assess safety and efficacy of blood pressure lowering in any patient 
with acute stroke. The analyses will include patient data (including stroke mimic 
patients) from all trials of blood pressure lowering in acute stroke. Patients with a 
confirmed stroke or TIA diagnosis will then be analysed separately.  
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Crosscutting neuroimaging theme 
Of relevance to all of the above questions will be assessment of baseline brain scans 
(CT or MRI) and, where available, on-treatment neuroimaging. Although much work 
has already been published on these for individual trials (e.g. (17-19)), aggregation of 
data will provide additional statistical power, especially in subgroups. Such analyses 
will be facilitated by the commonality of data collected across the trials. 
 
Statistical analysis 
A full statistical analysis plan is not given here because of the multi-phasic nature of 
this programme of work. The analyses will be performed using the intention-to-treat 
dataset from each trial, as defined by each individual trial. Initial internal analyses will 
compare baseline and outcome data from each trial with their published results to 
ensure that data are complete and transferred without error. Baseline characteristics 
will also be compared between individual trials to identify differences in patient 
characteristics. Since individual trial results have already been published, results from 
analysis of individual trials will not be identifiable in BASC publications.  
 
The primary effect variable (mRS) will be analysed using ordinal logistic regression; 
the assumption of proportionality of odds will be tested using the likelihood ratio test. 
Mixed effect analyses will be performed with adjustment for key baseline variables 
including age, sex, pre-morbid mRS, stroke type (ischaemic, haemorrhagic), stroke 
severity, stroke syndrome, systolic blood pressure, and time from stroke onset to 
randomisation; the source trial will be added as a random effect. For completeness, 
unadjusted analyses will also be performed. Analyses will be performed in key 
subgroups, as listed in Table 1, with addition of an interaction term to a mixed-effects 
OLR model. Subgroup analyses will include tests for heterogeneity by adding an 
interaction term into the adjusted ordinal logistic regression model. The effect of time 
from onset to treatment on potential efficacy (mRS) and hazard (death) will be 
assessed using a multiple variable regression model, as used previously for alteplase, 
thrombectomy and glyceryl trinitrate (14, 20, 21). Since each phase of the 
programme is likely to be analysed only once or twice, adjustment for multiple repeat 
analyses, as proposed for thrombectomy (22), will not be performed. 
 
Secondary outcomes will be analysed using adjusted Cox proportional hazards 
regression, binary logistic regression, ordinal logistic regression, or multiple linear 
regression, as appropriate. Multilevel models will compare blood pressure lowering 
with control interventions taking into account the differences between trials. These 
will include the same variables listed above for covariate adjustment. 
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DISCUSSION 
 
Phase III of the Blood Pressure in Acute Stroke Collaboration (BASC) will use pooled 
individual patient data from completed randomised controlled trials to address the role 
of blood pressure management in the acute phase of stroke. Conflicting results from 
multiple clinical trials indicate that blood pressure reduction is not a straightforward 
question of whether to treat or not. Rather, this problem is complex and needs to take 
account of patient characteristics, physiological parameters including baseline blood 
pressure, stroke type, timing of treatment, strategy and class of antihypertensive 
agent, route of administration, and dose or target blood pressure. The question of 
whether or not to reduce blood pressure in stroke has been debated for decades. 
Observational data have indicated consistently that acute elevation in blood pressure 
is common in stroke (75% of IS and 80% of ICH), is usually present during the first 
24 hours, and is often self-limiting (2). Further, high blood pressure is a poor 
prognostic sign for all stroke types and subtypes. 
 
For ICH, elevated baseline systolic blood pressure is associated with haematoma 
expansion (23), perihaematoma oedema formation (24), and increased mortality 
(25). There is increasing evidence that intensive lowering of blood pressure reduces 
haematoma enlargement (26), is safe and tolerable, does not alter cerebral blood flow 
(27), and decreases rates of neurological deterioration. Current guidelines recommend 
lowering blood pressure early in the course after ICH and that targeting a goal of 
SBP<140 mmHg is probably safe in patients presenting with a SBP of 150 to 220 mm 
Hg (4, 5). Nevertheless, the neutral findings of ATACH-2 (6) emphasise that re-
appraisal of all published data is again required. Although guidelines recognise the 
need for very early treatment, none address the role of pre-hospital blood pressure 
reduction.  
 
In ischaemic stroke, the rationale for lowering blood pressure is based on associations 
of acute high blood pressure with early recurrence and late death and dependency 
(2). It has been argued that high BP protects the brain by preserving ischaemic 
penumbra and that antihypertensive therapy may reduce cerebral perfusion, leading 
to poor outcomes. Elevated BP in the setting of failed autoregulation may maintain 
cerebral perfusion, but comes at the cost of increased cerebral oedema and 
haemorrhagic transformation. Clinical studies have shown mixed results, in part 
differentiated by drug class: whilst trials of angiotensin receptor antagonists, ß-
receptor antagonists and first-generation calcium channel blockers were negative, 
studies of enalapril and glyceryl trinitrate were neutral (7, 28, 29). Provisional 
evidence suggests that glyceryl trinitrate given within 4-6 hours might be beneficial 
(8, 30), as is being tested prospectively (15). Hence, whether to lower blood pressure 
per se may not be the relevant question in IS; rather, it may be what is the 
appropriate agent and timing in which to do so, and can this be done without 
compromising cerebral blood flow. 
 
Furthermore, the influence of patient characteristics that are present prior to the ICH 
or ischaemic stroke on BP lowering interventions is unknown, although these same 
variables are known to worsen long term recovery after both ICH and ischaemic 
stroke. These include having a prior stroke, white matter lesions or brain atrophy.  
 
The Blood Pressure in Acute Stroke Collaboration is an ongoing international 
collaborative project that will curate and analyse individual patient data from a wide 
variety of clinical trials to address the core questions related to acute blood pressure 
reduction in stroke. The collaboration is open to all randomised controlled trials in 
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which subjects were randomised to blood pressure treatment versus control in the 
acute phase of stroke. 
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Table 1. Prespecified subgroup analyses based on baseline characteristics.  
 
Type of subgroup Subgroup 
Biological Age 
 Sex 
 Race-ethnicity-region 
Clinical Systolic blood pressure 
 Heart rate 
 Stroke severity (NIHSS, or converted from SSS (31)) 
 Atrial fibrillation 
Pathophysiology and 
aetiology 
Stroke type (intracerebral haemorrhage, ischaemic 
stroke) 
 Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification (32) 
 Oxfordshire community stroke project (OCSP) 
classification (33) 
Neuroradiological Acute lesion visibility, location, associated features 
 Presence/extent of vessel thrombus  
 Presence/extent intraventricular blood 
 Small vessel disease score (34) 
 White matter lesion score (35) 
 Brain atrophy score 
 Prior stroke lesion 
Intervention Treatment modality 
 Drug class/target blood pressure 
 Route of administration 
 Time to treatment (or randomisation if not available) 
 Intravenous reperfusion, e.g. alteplase 
 Intra-arterial reperfusion, e.g. thrombectomy 
 Pre-stroke antihypertensive medication 
 
NIHSS: National Institutes of Health Stroke Scale; SSS: Scandinavian Stroke Scale 
 
 
 
 
